ACUTAAS3,458.40

Acutaas Chemicals Ltd.

· Pharma & Health
₹ CrorePeersANURASAETHERBLUEJETCAPLIPOINTCONCORDBIOEMCUREJBCHEPHARMERISMcap ₹28,314 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)129.97115.26141.91141.91
Receivable Days (DSO)104.98105.3198.8098.80
Payable Days (DPO)111.6299.9694.4285.55
Cash Conversion Cycle (days)123.33120.61146.29155.16
Working Capital Turnover3.411.712.062.25
Asset Turnover0.650.650.680.68
Cash Conversion (CFO/Net Income)2.570.740.820.82
CFO/EBITDA0.970.510.610.61
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.